Scorpion Therapeutics

View the org chart displaying its 22 main executives

Most searched biographies at Scorpion Therapeutics

• Arjun Goyal, Director
• Otello Stampacchia, Director
• Saurabh Saha, Director

Popular executive movements at Scorpion Therapeutics

• Michael Streit, Chief Medical Officer, has left the company  (posted on January 5 2024).
• Axel Hoos, Chief Executive Officer and Director, has left the company  (posted on January 5 2024).
• Mark Chao has joined the company as Chief Medical Officer  (posted on January 5 2024).

Create your alert
to follow the executive moves at Scorpion Therapeutics.

Scorpion Therapeutics has 2,290 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Delphia Therapeutics has just announced a $67 Million fundraising (posted on May 7 2024).
• Karius has just announced a $100 Million fundraising (posted on May 3 2024).
• Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Vik Bajaj - Director at Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by Scorpion Therapeutics

• Scorpion Therapeutics Appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and Expands Leadership Team - Scorpion Therapeutics
• Scorpion Therapeutics Appoints Precision Medicine Leader Jeff Albers as Strategic Advisor - Scorpion Therapeutics
• Scorpion Therapeutics Presents Preclinical Data for STX-241, a Fourth-Generation EGFR Inhibitor, at the AACR-NCI-EORTC Symposium 2023 - Scorpion Therapeutics
• Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer - Scorpion Th
• Scorpion Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of STX-478, Its Mutant-Selective PI3Kα Inhibitor for the Treatment of Breast Cancer and Other Solid Tumors - Scorpion Therapeutics
• Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer - Scorpion Therapeutics
• Scorpion Therapeutics Nominates STX-241 as Potentially Best-in-Class Fourth-Generation EGFR Inhibitor Development Candidate for the Treatment of Non-Small Cell Lung Cancer - Scorpion Therapeutics
• Scorpion Therapeutics Presents Preclinical Data for Potential Best-in-Class PI3Kα Inhibitor at San Antonio Breast Cancer Symposium - Scorpion Therapeutics
• Scorpion Therapeutics to Present Preclinical Data for Potential Best-in-Class Mutant-Selective PI3Kα Inhibitor at San Antonio Breast Cancer Symposium - Scorpion Therapeutics
• Scorpion Therapeutics Announces Formation of World-Class Clinical Scientific Advisory Board - Scorpion Therapeutics
• View more press releases Close

Social media about Scorpion Therapeutics

• Scorpion Therapeutics on Wikipedia, Google News & Yahoo Finance
• Scorpion Therapeutics on LinkedIn, Twitter & YouTube

Contact by email its executives including Shelley Chu

Call Scorpion Therapeutics at +1 212...

View the org chart

Register to receive your alert

Report an error